ADARx (ADRX) CTO Zhu Rui Receives Award of 512,076 Shares

What Happened
Zhu Rui, Chief Technology Officer of ADARx Pharmaceuticals, was granted 512,076 derivative shares (reported as an award, code A) on September 24, 2026. The filing lists a $0.00 per-share price, so the reported transaction value is $0 — this is a compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-24; Form 4 filed: 2026-09-28 (appears to be filed 4 days after the grant; Form 4s are normally due within two business days).
• Transaction type: Grant / award of derivative securities (code A).
• Shares granted: 512,076; price per share: $0.00; reported value: $0.
• Vesting (footnote F1): 1/4 of the total vests and becomes exercisable on September 24, 2027; remaining shares vest in equal quarterly installments thereafter over a three-year period, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax withholding, or cashless exercise details are reported in the excerpt.

Context
This is a time‑based compensation award (a derivative grant) that will convert to exercisable/vested rights over several years if the reporting person remains employed — it is not an immediate purchase or sale. Such grants are common for key executives as retention/compensation and do not by themselves indicate a near‑term market view. The apparent late filing may be worth noting — check the complete SEC filing and subsequent reports for full ownership details and any corrections.